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Objective: To identify plasma biomarkers for the diag-
nosis of Alzheimer disease (AD).
Design: Baseline plasma screening of 151 multiplexed
analytes combined with targeted biomarker and clinical
pathology data.
Setting: General community-based, prospective, lon-
gitudinal study of aging.
Participants: A total of 754 healthy individuals serv-
ing as controls and 207 participants with AD from the
Australian Imaging Biomarker and Lifestyle study (AIBL)
cohort with identified biomarkers that were validated in
58 healthy controls and 112 individuals with AD from
the Alzheimer Disease Neuroimaging Initiative (ADNI)
cohort.
Results: A biomarker panel was identified that in-
cluded markers significantly increased (cortisol, pancre-
atic polypeptide, insulinlike growth factor binding pro-
tein 2, 2 microglobulin, vascular cell adhesion molecule
1, carcinoembryonic antigen, matrix metalloprotein 2,
CD40, macrophage inflammatory protein 1, superox-
ide dismutase, and homocysteine) and decreased (apo-
lipoprotein E, epidermal growth factor receptor, hemo-
globin, calcium, zinc, interleukin 17, and albumin) in AD.
Cross-validated accuracy measures from the AIBL co-
hort reached a mean (SD) of 85% (3.0%) for sensitivity
and specificity and 93% (3.0) for the area under the re-
ceiver operating characteristic curve . A second valida-
tion using the ADNI cohort attained accuracy measures
of 80% (3.0%) for sensitivity and specificity and 85% (3.0)
for area under the receiver operating characteristic curve.
Conclusions: This study identified a panel of plasma bio-
markers that distinguish individuals with AD from cog-
nitively healthy control subjects with high sensitivity and
specificity. Cross-validation within the AIBL cohort and
further validation within the ADNI cohort provides strong
evidence that the identified biomarkers are important for
AD diagnosis.
Arch Neurol. 2012;69(10):1318-1325. Published online
July 16, 2012. doi:10.1001/archneurol.2012.1282
A LZHEIMER DISEASE (AD) ISthe most common form ofdementia, affecting morethan 27 million personsworldwide and predicted
to affect 86 million people by the year
2050.1 The disease is characterized mor-
phologically by an overall loss of syn-
apses and neurons and an overall reduc-
tion in brain volume.2 The identification
of peripheral biomarkers of the disease
process leading to an effective and early
diagnostic test for AD would allow for pre-
symptomatic detection of disease and
would be valuable for monitoring the ef-
ficacy of disease interventions during
clinical trials.
Currently, cerebrospinal fluid (CSF) has
provided the most promising source of
validated AD biomarkers. A decline in
-amyloid (A) levels in the CSF has been
reported to help distinguish between pa-
tients with AD and elderly individuals
without AD.3-7 In particular, the longer 42–
amino acid isoform A1-42 in combina-
tion with levels of the phosphorylated mi-
crotubule-associated protein tau (p-tau)
has been advocated for use in the diagno-
sis of AD.8 Perrin and colleagues9 identi-
fied other biomarkers, including neuro-
nal cell adhesion molecule, YKL-40 (YKL
represents the first 3 N-terminal amino ac-
ids and 40 denotes molecular mass in
kilodaltons; also known as human chitin-
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ase 3–like 1, cartilage glycoprotein 39, and chondrex),
chromogranin A, and carnosinase I, which improved the
diagnostic accuracy of A1-42 and p-tau. Craig-
Schapiro and colleagues10 used a biomarker discovery
method from rules-based medicine (RBM) to identify
novel CSF biomarkers that distinguish between very mild
dementia, mild dementia, and no dementia.
Compared with CSF, blood analysis has advantages as
an approach to population-based disease screening be-
cause it is simpler and less invasive. As such, there has been
strong interest in obtaining usable blood-based biomark-
ers for AD diagnosis. Ray et al11 identified a panel of 18 bio-
markers from a group of 120 signaling proteins and, more
recently, O’Bryant and colleagues12,13 used a panel from RBM
to identify a list of 30 biomarkers to detect AD. Soares and
colleagues14 describe a list of biomarkers identified within
the Alzheimer Disease Neuroimaging Initiative (ADNI) co-
hort in this issue. Herein, we describe a short articulated
panel of blood-based biomarker candidates obtained by
comparing clinical factors with blood-based measures from
the Australian Imaging, Biomarkers and Lifestyle (AIBL)
study, a prospective longitudinal cohort study of aging in
Australia.15 This biomarker panel was then validated in the
ADNI cohort. The biomarkers identified in this cross-
sectional analysis of data from the AIBL study may con-
tribute toward the development of a blood-based diagnos-
tic test,which togetherwithappropriate imagingphenotypes
may deliver an accurate means to diagnose AD.
METHODS
STUDY COHORTS, SAMPLE PREPARATION,
AND MULTIPLEX PANEL
This study refers to initial biomarker screening in 754 healthy
individuals serving as controls (HCs) and 207 participants with
AD, drawn from the AIBL study.15 Blood samples were col-
lected from all patients (fasting) on arrival at both Australian
sites and were fractionated within 2 hours of collection and snap
frozen in liquid nitrogen.15 Full blood pathology testing (Mel-
bourne Health and PathWest Laboratory Medicine) and apo-
lipoprotein E (APOE; OMIM 107741) genotyping,16 were per-
formed. The APOE genotype discussed within this article relates
to testing all possible APOE genotypes.
Plasma (EDTA plus 33 ng/mL prostaglandin E1; Sapphire
Biosciences) samples from the AIBL cohort were analyzed with
a 151-analyte multiplex panel (Human DiscoveryMAP, ver-
sion 1.0; RBM). All sample results below the lower limit of quan-
titation were classed as missing data. Plasma A1-40 and A1-42
peptides were measured using a commercial assay (INNO-BIA
plasma A assay; Innogenetics, Inc) and a well-documented
double sandwich enzyme-linked immunoassay tech-
nique,5,17,18 as described previously.19 Total APOE and APOE4
protein levels were measured in plasma from fasting partici-
pants using a commercial assay (APOE4/Pan APOE ELISA; MBL
Co, Ltd), as previously described.20 Total plasma (lithium hep-
arin) metal iron levels were measured by induction-coupled
plasma mass spectrometry. Seven metals were measured: chro-
mium (isotopes 52 and 53; Cr), copper (isotope 65; Cu), iron
(isotope 57; Fe), rubidium (isotope 85; Rb), selenium (iso-
tope 78; Se), and zinc (isotope 66; Zn). All available data from
a subset of the ADNI study cohort (HC, 58; AD, 112) mea-
sured for the RBM protein analyte panel and various clinical
pathology measures were used for validation purposes. Infor-
mation regarding biological preparation of ADNI samples and
analysis of the RBM Human DiscoveryMAP panel can be found





To compare the basic demographic statistics between the co-
horts, 2 analyses (P value from Fisher exact test when neces-
sary) and Mann-Whitney tests were used. A generalized linear
model was used, adjusted for age, sex, and APOE genotype, to
determine overall biomarker differences between HC and AD
individuals. Using the Bonferroni multiple adjustment ap-
proach, the  value for P value comparison was .0003 (.05/
174). Fold protein change was calculated using unadjusted raw
expression values to provide a relative protein difference be-
tween HC and AD individuals. The R statistical software envi-
ronment, version 2.10, was used for all statistical analyses.24
Method Overview
A preanalysis stage (eAppendix) was implemented incorporat-
ing data cleaning, transformation, and imputation (values avail-
able on request from the corresponding author). Subse-
quently, variable selection and class prediction analyses were
conducted to choose a short list of blood-based protein bio-
markers to predict AD. Two sets (primary and validation) of
variable selection techniques were used, with findings vali-
dated with linear support vector machine analyses. Figure 1
provides an overview of the statistical approaches used; ex-
panded details of biomarker selection, cross-validation, and pre-
diction validation are provided in the eAppendix. Variable se-
lection approaches were conducted independently, and results
were collated. Biomarkers were chosen for further analyses if
they were selected in each variable selection method. Find-
ings were validated using the secondary cohort, ADNI. Sample














Approach 1: Age, sex, and
 APOE genotype
Approach 2: Age, sex, APOE genotype,
 and biomarker set A
Approach 3: Age, sex, APOE genotype,
 and biomarker set B
Feature selection and
class prediction
Figure 1. Statistical method mind-map. Defines commonly used terms for
statistical analyses pathways 1 and 2, statistical methods sets 1 and 2, and
model prediction approaches 1, 2, and 3. APOE indicates apolipoprotein E;
LIMMA, linear models for microarray; SAM, significance analyses of
microarray; and SVM, support vector machine.
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Baseline sample characteristics of the AIBL and ADNI co-
horts for demographic and clinical classifications are pre-
sented in Table 1. Comparisons were undertaken be-
tween cohorts with respect to HCs, AD cases, and a
combined overall grouping. Significant distributional dif-
ferences were found for age, educational level, APOE geno-
type, and Clinical Dementia Rating (CDR) score; no sig-
nificant differences in the distributions of body mass index
(BMI; calculated as weight in kilograms divided by height
in meters squared) and sex across the 2 cohorts were ob-
served (Table 1). When the groups were stratified, the
proportions of AD participants were very similar for both
CDR and APOE genotype, whereas the proportions of HCs
for the same demographic variables were significantly dif-
ferent (CDR, P=.0004; APOE genotype, P=.003). On av-
erage, the Mini-Mental State Examination score was lower
in AIBL AD participants than in ADNI AD participants,
whereas HCs in both cohorts had the same Mini-Mental
State Examination score. Comparing age between co-
horts, the AIBL cohort had a higher proportion of younger
(70 years) HCs than did the ADNI cohort (35% vs 4%)
and also had a higher proportion of older (80 years)
participants with AD (68% vs 52%). Healthy controls from
the AIBL cohort tended to have more years of education
compared with those from the ADNI, and there was a
higher proportion of HCs in the ADNI cohort who had
a CDR score of 0.5.
In addition to the cohort comparisons presented
in Table 1, BMI and educational levels were compared
between the AD and HC groups (AIBL sample data). Data
on educational level were collected using published stan-
dards15 (Table 1); however, for the purposes of these analy-
ses, 3 groups were created (9, 9-12, and 13 years
of education). Compared with HCs, the AD group was
3.7 times more likely to have fewer than 9 years of edu-
cation (P  .0001). Body mass index was categorized
into 3 levels (25, 25-30, and 30). Healthy controls
were 2.8 times as likely to have BMIs greater than 30 than
were individuals with AD (P = .002).











(n = 108) HC AD Overall
Age, y
70 261 (35) 22 (11) 2 (4) 19 (18)
.0001 .02 .000170-79 333 (45) 41 (21) 32 (56) 33 (31)
80 149 (20) 132 (68) 23 (40) 56 (52)
Sex
Male 319 (42) 80 (39) 28 (49) 47 (44)
.32 .40 .24
Female 435 (48) 127 (61) 29 (51) 61 (56)
Educational level, y
0-6 5 (1) 12 (6) 0 2 (2)
.0001c .0001c .0001c
7-8 56 (7) 34 (17) 19 (33) 23 (21)
9-12 284 (38) 73 (36) 32 (56) 59 (55)
13-15 149 (20) 36 (18) 1 (2) 3 (3)
15 257 (34) 46 (23) 5 (9) 21 (19)
BMI
25 294 (41) 77 (54) 18 (32) 50 (46)
.43 .44 .6825-29.9 298 (41) 53 (37) 26 (46) 46 (43)
30 128 (18) 12 (8) 12 (21) 12 (11)
MMSE score, mean (SD) 28.9 (1.2) 18.9 (5.3) 28.9 (1.2) 23.6 (1.9) .81 .0001 .0001c
CDR score
0 714 (95) 0 46 (82) 0
.0004c .19c .0001c
0.5 38 (5) 65 (31) 10 (18) 40 (37)
1 1 (0.1) 113 (55) 0 60 (56)
1 0 29 (14) 0 8 (7)
APOE ε4
Negative 572 (76) 79 (38) 53 (93) 35 (32)
.003 .31 .0003
Positive 182 (24) 128 (62) 4 (7) 73 (68)
Abbreviations: AD, Alzheimer disease; ADNI, Alzheimer Disease Neuroimaging Initiative; AIBL, Australian Imaging Biomarker and Lifestyle study;
APOE, apolipoprotein E; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CDR, Clinical Dementia Rating;
HC, healthy controls; MMSE, Mini-Mental State Examination.
aCross-tabulation frequencies are shown for demographic and clinical characteristics of the AIBL and ADNI cohorts between the HC and AD groups.
bP values were calculated from the comparison of the 2 cohorts with and without stratification for clinical classification. Educational level shown as per ADNI
classifications (ADNI Enrol: Demographics). Missing data were observed within AIBL for educational level (HC, 3; AD, 6), BMI (HC, 34), MMSE (HC, 4), and CDR
(HC, 1).
cRepresents the P value used from the Fisher exact test.
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BIOMARKER DATA SET COMPARISONS
After data cleaning and imputation, characterization of
the biomarker data sets from the AIBL and ADNI co-
horts revealed that, of the multiplexed biomarkers as-
sayed, 111 were suitable for analysis from the AIBL co-
hort and 136 were suitable from the ADNI cohort
(remaining biomarkers had 10% missing values). Of
these, 96 were common to both cohorts. In addition to
these protein markers, 52 standard clinical pathology
markers, 7 markers of metal ions, and circulating levels
of A1-40 and A1-42 were measured in the AIBL co-
hort. Thirty-eight clinical pathology markers were avail-
able from the ADNI cohort, of which 22 matched those
from AIBL.
Comparing protein values between HCs and AD pa-
tients, 21 biomarkers showed a significant fold change
(P  .0003) (Table 2) from the AIBL cohort, but only
2 biomarkers from the ADNI cohort were altered at this
level of significance (P  .0003). The eTable compares
the top 21 biomarkers from the AIBL and ADNI cohorts
from variable selections, according to fold change. Bio-
markers among the top 21 from both the AIBL and ADNI
cohorts included pancreatic polypeptide (PPY), tissue in-
hibitor of metalloproteinases 1, tumor necrosis factor re-
ceptor–like 2, and vascular cell adhesion molecule 1
(VCAM1). Analytes only available in the AIBL cohort that
were significantly altered in the AD participants com-
pared with HCs (P  .0003) included homocysteine, in-
terleukin 10 (IL-10), IL-17, and zinc.
BIOMARKER SELECTION
IN THE AIBL COHORT
From a total of 174 biomarkers, 18 markers were se-
lected in the AIBL cohort: 11 markers from the RBM ar-
ray, 5 clinical pathology variables, 1 metal ion, and the com-
mercial assay for APOE (Table 2). Of the 21 biomarkers
that showed a significant fold change in AD patients com-
pared with HCs, 6 biomarkers that were selected using the
suites of variable selection methods did not reach signifi-
cance once they were adjusted for age, sex, APOE geno-
type, and Bonferroni multiple comparisons (Table 2). The
protein fold difference between AD patients and HCs was
highest for insulinlike growth factor binding protein 2 (IG-
FBP2) (1.61-fold). Pancreatic polypeptide was the only
other protein that was at least 1.5-fold greater in AD pa-
tients compared with HCs (1.54-fold).
Biomarkers were selected for prediction if they were
chosen from all 4 statistical methods in set 1 (random
forest, boosted trees, regression trees, and linear models
for microarray), and were then validated using set 2 (best
first, greedy stepwise, forward selection regression, and
significance analyses of microarray) or recursive feature
elimination–support vector machine. The number of bio-
markers that were selected by these methods and that were
common between the sets is illustrated in Figure 2. Bio-
markers that were selected in at least 2 of 3 methods (21
biomarkers) were subject to statistical analysis pathway
2. Further statistical assessment of the 21 biomarkers
(stepwise removal of biomarkers based on predictive ac-
curacy) removed 3 biomarkers (tumor necrosis factor re-
ceptor–like 2, tissue inhibitor of metalloproteinases 1, and
vascular endothelial growth factor), leaving a final panel
of 18 biomarkers (biomarker set A; Table 2).
DISEASE PREDICTIONS
Model predictions in the AIBL cohort (Figure 3A) for
the demographic variables (age, sex, and APOE geno-
type) resulted in a sensitivity and specificity (SD) of 77%
(3.0%) and an area under the receiver operating charac-
teristic curve (AUC) of 84% (3.0%). Adding biomarker
set A to age, sex, and APOE genotype improved the sen-
sitivity and specificity to 85% (3.0%) and the AUC to 89%
(3.0%). Reducing the number of biomarkers to 8 (cor-
tisol, IGFBP2, PPY, IL-17, VCAM1, 2 microglobulin
[B2M], epidermal growth factor receptor, and carcino-
embryonic antigen; biomarker set B) reduced the sensi-
tivity and specificity by only 2%. Adding covariates such
as educational level and BMI increased the sensitivity and
specificity by 0.5% in all models.
Table 2. AIBL Biomarkers With Significantly Altered Levels
Between AD Participants and Healthy Controls
AIBL Biomarkera Foldb P Valuec
Insulinlike growth factor binding protein 2d 1.61 .0001
Pancreatic polypeptided 1.54 .0001
Erythrocyte sedimentation rate 1.46 .002
B lymphocyte chemoattractant 1.45 .002
Carcinoembryonic antigend 1.40 .001
Cortisold 1.28 .0001
Tumor necrosis factor receptorlike 2 1.27 .0002
Homocysteinee 1.23 .002
Angiopoietin 2 1.23 .003
Matrix metalloproteinase 9 1.19 .001
Vascular cell adhesion molecule 1d 1.18 .0001
Tissue inhibitor of metalloproteinases 1 1.18 .0003
Superoxide dismutasee 1.16 .0001
Alpha 1 antitrypsin 1.11 .0003
Interleukin 10 1.10 .0001




Zinc (isotope 66)e 0.91 .0001
Interleukin 17d 0.87 .0001
2 microglobulind 1.24 .006
CD40e 1.21 .040
Matrix metalloproteinase 2e 1.13 .101
Macrophage inflammatory protein 1e 1.12 .006
Apolipoprotein E (commercial assay)e 0.97 .042
Epidermal growth factor receptord 0.89 .012
Abbreviations: AD, Alzheimer disease; AIBL, Australian Imaging Biomarker
and Lifestyle.
aBiomarkers are ranked in order of fold overexpression and
underexpression in patients with AD compared with healthy controls (HCs),
calculated by dividing the raw unadjusted protein/clinical biomarker level in
the AD group by the HC group.
bFor fold regulation, a value less than 1 indicates downregulated in AD;
a value greater than 1, upregulated in AD.
cP values are shown from a generalized linear model, adjusted for age,
sex, and APOE genotype. Rank does not indicate the level of importance,
with tags attached to specific biomarkers denoting the importance of
proteins within the identified biomarker signatures.
dBiomarkers contained within biomarker set A and set B.
eBiomarker contained within biomarker set A.
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VALIDATION
To validate the initial biomarker findings from the AIBL
cohort, we used 2 different approaches. First, we cross-
validated the AIBL data using only variables that were
available in both cohorts; second, we used the ADNI data
as the validation set on which to predict the biomarker
model (Figure 3B). Using the first approach (IL-17, zinc,
and homocysteine were removed), we obtained sensitiv-
ity and specificity (SD) of 83% (3.0%) and an AUC of
87% (3.0%). With ADNI protein data for validation (the
second approach), reduced accuracy statistics were iden-
tified; however, the shorter biomarker set B performed
better than the longer biomarker set A (set A minus
IL-17, zinc, and homocysteine: sensitivity and specific-
ity [SD], 77% [4.0%]; AUC, 84% [4.0%]; set B minus
IL-17: sensitivity and specificity, 80% [3.0%]; AUC 85%
[3.0%]).
COMMENT
In this study, we identified an 18-biomarker signature
panel for the diagnosis of AD in the AIBL cohort and vali-
dated them in the ADNI population. We showed that in-
cluding demographic and clinical information (educa-
tional level and BMI) together with these blood-based
biomarkers and adjusting for age, sex, and APOE geno-
type strengthens the accuracy of disease prediction.
The validation analyses using both cohorts demon-
strated the strength of the chosen biomarkers. Reducing
the number of biomarkers in the signature panel to 8
(B2M, carcinoembryonic antigen, cortisol, epidermal
growth factor receptor, IGFBP2 IL-17, PPY, and VCAM1)
using the AIBL data reduced the accuracy of the predic-
tion by only 2%; the same reduction using the ADNI data
as the validation set increased the prediction accuracy
over using the full set of 18 biomarkers. Reducing the
signature of biomarkers in the diagnostic panel in-
creases its usefulness, initially within the clinical setting
and after further validation for population screening. We
acknowledge that the differences between the 2 co-
horts, such as the reduced number of samples, the ratio
of AD patients to HCs, and the differences in age, edu-
cational status, CDR score, and APOE ε4 allele status, may
all play a role in validation accuracy.
From all biomarkers identified, cortisol, IGFBP2, and
PPY were the ones most frequently chosen. The eleva-
tion of cortisol in AD participants presented herein and
its presence as a part of the biomarker signature are in
concordance with previously published studies.25 More-
over, Lupien et al26 found that prolonged exposure to the
adrenal glucocorticoid aligns with reduced hippocam-
pal volume and hippocampus-related memory tasks. Por-
ter and Landfield27 proposed multiple hypotheses re-
garding the aging effects of prolonged exposure to adrenal
hormones and suggested that the interaction between ag-
ing, stress, and glucocorticoids increases vulnerability and
cognitive impairment. The effects of chronic glucocor-
ticoid exposure and hippocampal volume in animal mod-
els have been summarized by Tata and Anderson.28 Re-
cently, McAuley et al29 showed, from an in silico model,
a potential 30% to 40% decrease in hippocampal activ-
ity with long-term elevated levels of cortisol. They showed
that a biological intervention to such a system might re-
duce the decrease of hippocampal activation by 22%. How-
ever, subsequent reports have shown that cortisol is both
a putative biomarker, as part of a large panel, for the clas-
sification of patients with schizophrenia30 and is el-
evated in that population.31 These data, together with the
results from the present study, indicate that further re-
search validating cortisol levels across different neuro-
logic diseases is required to determine its specificity.
In addition to the present study on blood-based bio-
markers, IGFBP2 was found to be higher in the CSF of
individuals with AD in 2 other studies.32,33 The second
of these studies33 reported a significant increase in IGFBP2
in both CSF and serum. A more recent study,10 using the
same multiplex panel as in the present study, failed to
detect a significant change in IGFBP2 levels in the CSF
of patients with AD; however, IGFBP2 was correlated with
the levels of CSF tau. To the best of our knowledge, the
study of Craig-Schapiro and colleagues10 has been the only
other one to find PPY and IL-17 significantly altered in
the CSF of individuals with AD compared with the CSF
of HCs.
Davidsson et al34 identified B2M along with APOE and
others as significantly altered proteins in the CSF of par-
ticipants with AD compared with healthy controls. Our
study showed increased B2M levels among patients with
AD compared with controls; B2M is a small component
of the major histocompatibility complex class I heavy
chain and is involved with membrane turnover and elimi-
nation. Furthermore, because there is evidence that B2M
is increased in other diseases in which the immune re-
sponse is elevated, research has suggested that it is a
marker of the immunologic state in vivo.35







Figure 2. Biomarker Venn diagram. This diagram defines the numbers of
protein biomarkers selected by each of the 2 statistical methods sets (set
1/set 2) and support vector machine (SVM) analyses. Overlap between
3 circles defines the number of markers chosen by all 3 groups; overlap
between 2 circles defines the number of markers that were chosen by the
2 overlapping circle groups. The numbers in the black circles define how the
initial 21-biomarker list was achieved.
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To our knowledge, this study is the first to show a re-
lationship between epidermal growth factor receptor and
AD. Zhang et al36 found that the Alzheimer A precur-
sor protein intracellular domain (released as a result of
	 secretase cleavage) mediated the transcriptional regu-
lation of epidermal growth factor receptor. It is thus pos-
sible that in the presence of abnormal A amyloid pre-
cursor protein there may be a corresponding increase in
the transcription of epidermal growth factor receptor and
an increase in serum levels of EGFR. Further research
focused on the gene expression of EGFR is currently un-
der way to validate this hypothesis.
Carcinoembryonic antigen has not previously been
found to be associated with AD. Carcinoembryonic an-
tigen, like VCAM1, is a cell adhesion molecule and be-
longs to a large family of immunoglobulins. O’Bryant et
al12 suggested an inflammatory endophenotype of AD from
the large proportion of inflammatory markers identified
in their study. Our finding of markers such as carcino-
embryonic antigen, VCAM1, IL-17, macrophage inflam-
matory protein 1 , and B2M is related to immune sys-
tem functionality and supports the hypothesis that there
is an inflammatory endophenotype in AD.
Our results agree with those of O’Bryant and col-
leagues12,13 in that there is an abundance of inflamma-
tory markers in our findings; however, this may be the
result of the high proportion of inflammatory markers
in the RBM panel used in both studies by O’Bryant et
al12,13 and in our study. Certainly, newer RBM bio-
marker panels have more proteins from multiple path-
ways represented.
We also report considerable overlap with biomarkers
identified by Soares and colleagues,14 in particular with
respect to univariate analyses, for which increased lev-
els of N-terminal pro–brain natriuretic peptide (NT-
proBNP), eotaxin 3, matrix metalloproteinase 1, PPY,
and tenascin C and decreased levels of IgM and APOE
were reported. Furthermore, multivariate analyses iden-
tified that APOE and NT-proBNP were of particular
importance in contributing to the increased accuracy of
the classification of AD.14 Although we also identified
decreased APOE (in biomarker set A), NT-proBNP was
not included in the multiplexed panel used in this
study; however, its identification in CSF by Craig-
Schapiro and colleagues10 provides evidence of its prob-
able importance in AD. Likewise, there is growing sup-
port for the importance of APOE protein levels as a
biomarker for disease.14,20
We performed rigorous statistical analyses of a large
biomarker set from the AIBL study and validated these
results using comparable biomarker data from the ADNI
study. Using a suite of statistical methods, we found the
markers cortisol, PPY, IGFBP2, IL-17, VCAM1, B2M,
EGFR, and carcinoembryonic antigen to be part of a blood-
based signature to determine AD. We stress the impor-
tance that the biomarkers identified are blood based. Such
an improvement in diagnostic predictive power over the
base model of age, sex, and APOE ε4 allele has identified
the combinatorial strength of blood-based markers, in
which prior benchmarks are derived from highly sensi-
tive but invasive CSF testing. Selection of these biomark-
ers after such thorough statistical analysis and valida-
tion of these markers using a second cohort provide strong
evidence of their importance in AD pathogenesis and, in
turn, AD diagnosis. Whether their accuracy can be im-
proved in combination with biomarkers identified in re-





























Age, sex, and APOE genotype
Age, sex, APOE genotype, and biomarkers set A
Age, sex, APOE genotype, and biomarkers set B
AIBL validation
AIBL validation, ADNI markers
ADNI validation set A
ADNI validation set B
Figure 3. Receiver operating characteristic (ROC) curves for comparison of biomarker set performance in the Australian Imaging Biomarker and Lifestyle study
(AIBL) and the Alzheimer Disease Neuroimaging Initiative (ADNI) data sets. A, The ROC curves represent the area under the ROC curve (AUC) as tested using the
AIBL data only. The AUC comparison in the AIBL data set used (1) age, sex, and presence of the apolipoprotein E (APOE) ε4 allele (red line); (2) age, sex, APOE ε4
allele, and the 18-variable biomarker set A (green line); and (3) age, sex, APOE ε4 allele, and the reduced 8-variable biomarker set B (blue line). B, The ROC curves
represent a comparison between class predictions when using only AIBL protein biomarker data or when using ADNI protein biomarkers as the validatory data set.
The AUC comparison of 4 different prediction models used (1) the AIBL data set: age, sex, presence of the APOE ε4 allele, and biomarker set A (red line;
equivalent of green line in A); (2) cross validation of the AIBL data set using markers available from both cohorts, that is, age, sex, presence of the APOE ε4 allele,
and biomarker set A minus interleukin 17 (IL-17), Zn, and homocysteine (blue line); (3) the ADNI data set: age, sex, presence of the APOE ε4 allele, and biomarker
set A minus IL-17, Zn, and homocysteine (green line); and (4) the ADNI data set: age, sex, APOE ε4 allele, and biomarker set B minus IL-17 (yellow line).
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